A Prediction Rule to Stratify Mortality Risk of Patients with Pulmonary Tuberculosis by Bastos, H. et al.
RESEARCH ARTICLE
A Prediction Rule to Stratify Mortality Risk of
Patients with Pulmonary Tuberculosis
Helder Novais Bastos1,2,3*, Nuno S. Osório2,3, António Gil Castro2,3, Angélica Ramos4,5,
Teresa Carvalho4,5, Leonor Meira1, David Araújo1, Leonor Almeida1, Rita Boaventura1,
Patrícia Fragata6, Catarina Chaves2, Patrício Costa2,3,7, Miguel Portela8, Ivo Ferreira9, Sara
Pinto Magalhães9, Fernando Rodrigues2,3, Rui Sarmento-Castro2,3,10,
Raquel Duarte5,11,12,13, João Tiago Guimarães4,5,14, Margarida Saraiva2,3,15,16
1 Department of Pneumology, Centro Hospitalar São João, Porto, Portugal, 2 Life and Health Sciences
Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal, 3 ICVS/3B’s -
PT Government Associate Laboratory, Braga/Guimarães, Portugal, 4 Department of Clinical Pathology,
Centro Hospitalar São João, Porto, Portugal, 5 Institute of Public Health, University of Porto, Porto, Portugal,
6 Department of Internal Medicine, Hospital do Santo Espírito da Ilha Terceira, Angra do Heroísmo, Portugal,
7 Faculty of Psychology and Educational Sciences, University of Porto, Porto, Portugal, 8 School of
Economics and Management, University of Minho, Braga, Portugal, 9 Department of Radiology, Centro
Hospitalar do Porto, Porto, Portugal, 10 Department of Infectious Diseases, Centro Hospitalar do Porto,
Hospital Joaquim Urbano Unit, Porto, Portugal, 11 Department of Pneumology, Centro Hospitalar de Vila
Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, 12 Referral Centre for Multidrug-resistant tuberculosis
in the Northern Region of Portugal, Chest Disease Centre of Vila Nova de Gaia, Vila Nova de Gaia, Portugal,
13 General Directorate of Health, Lisboa, Portugal, 14 Department of Biochemistry, Faculty of Medicine,
University of Porto, Porto, Portugal, 15 i3S - Instituto de Investigação e Inovação em Saúde, University of
Porto, Portugal, 16 IBMC - Instituto de Biologia Molecular e Celular, University of Porto, Porto, Portugal
* hnovaisbastos@ecsaude.uminho.pt
Abstract
Tuberculosis imposes high human and economic tolls, including in Europe. This study was
conducted to develop a severity assessment tool for stratifying mortality risk in pulmonary
tuberculosis (PTB) patients. A derivation cohort of 681 PTB cases was retrospectively
reviewed to generate a model based on multiple logistic regression analysis of prognostic
variables with 6-month mortality as the outcome measure. A clinical scoring system was
developed and tested against a validation cohort of 103 patients. Five risk features were
selected for the prediction model: hypoxemic respiratory failure (OR 4.7, 95% CI 2.8–7.9),
age50 years (OR 2.9, 95% CI 1.7–4.8), bilateral lung involvement (OR 2.5, 95% CI 1.4–
4.4),1 significant comorbidity—HIV infection, diabetes mellitus, liver failure or cirrhosis,
congestive heart failure and chronic respiratory disease–(OR 2.3, 95% CI 1.3–3.8), and
hemoglobin <12 g/dL (OR 1.8, 95% CI 1.1–3.1). A tuberculosis risk assessment tool
(TReAT) was developed, stratifying patients with low (score2), moderate (score 3–5) and
high (score6) mortality risk. The mortality associated with each group was 2.9%, 22.9%
and 53.9%, respectively. The model performed equally well in the validation cohort. We pro-
vide a new, easy-to-use clinical scoring system to identify PTB patients with high-mortality
risk in settings with good healthcare access, helping clinicians to decide which patients are
in need of closer medical care during treatment.
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Introduction
Tuberculosis (TB) remains a major global health problem, with an estimated 9.6 million new
cases and 1.5 million deaths in 2014 [1]. In Portugal, the incidence was still 25/100.000 inhabi-
tants (intermediate incidence rate) and, contrasting to the majority of other European coun-
tries, most of the new TB cases are Portuguese native. A very recent report [2] analysed the
social profile of the highest TB incidence areas in Portugal between 2002 and 2012 and con-
cluded that immigrants comprised only 1.6 to 1.8% in the region of Porto, while the highest
proportion was seen in the Lisbon area (8.4–8.8%), where larger migration influx has occurred
mainly from sub-Saharan African former colonies. In spite of the greater incidence as com-
pared to other countries, treatment success rate in Portugal is high [1] and the case-fatality rate
has been below the European Union average [3], which accounts for the efficiency of the
national healthcare system.
An increased risk of death from TB has been attributed to drug resistance acquisition and
HIV coinfection, especially in developing countries with high incidence [3]. However, follow-
ing population-based epidemiological studies in regions of low and intermediate TB incidence,
other predictors of mortality have been identified. This was the case of increasing age, male
gender, the occurrence of extrapulmonary TB and several comorbidities [3–7]. Therefore,
objective clinical assessment of risk factors may help lowering the death rate associated with
TB by selecting those patients who might be in need of increased clinical supervision or
advanced medical treatment.
The use of clinical prediction rules (CPR) gained has relevance in the field of lung diseases
in the last decades [8]. Although several prediction scores have been developed in the field of
TB, most of them are available for diagnostic purposes [9–13], with only three providing prog-
nosis-centred CPRs [6, 14, 15]. Among these, none is representative of a low to intermediate
incidence region, with low rates of drug resistance, in both hospital and ambulatory settings. In
this context, we developed a TB risk assessment tool (TReAT) based on readily available clini-
cal features, with the aim of stratifying the risk of death among pulmonary TB (PTB) patients
and possibly helping on the decision for different management options.
Materials and Methods
Study design and patient population
For the derivation (training) set, the clinical records of patients withMycobacterium tuberculo-
sis positive culture at a University-affiliated hospital (Hospital São João—HSJ, Porto) during
the period of 7 years (2007–2013) were retrospectively analysed. TB cases were defined accord-
ing to the WHO guidelines and treatment was administered by DOT 5–7 days/week, with the
recommended treatment regimens [16]. Exclusion criteria were: i) exclusively extrathoracic
TB; ii) age<18 years and iii) lack of information (no registries found). Subjects were catego-
rized according to the disease site as: i) exclusively pulmonary; ii) pleural, with or without
proven PTB; or iii) combined extrathoracic and PTB. Extrathoracic involvement was defined
as disease in organs other than the lungs or pleura, with eitherM. tuberculosis culture isolation
or histologic demonstration of caseating granulomas [16].
The validation set was provided by the Chest Disease Centre (CDC) of Vila Nova de Gaia,
an ambulatory referral centre for TB screening and treatment in a large urban area of the north
of Portugal. Since mortality of patients diagnosed at the hospital is higher than what is
observed in the non-hospital setting, we forced a ratio cases (deaths) to controls (survivors)
similar to the derivation cohort, by using an entry-time-matched validation set. Cases that
immediately preceded and/or immediately followed each of the fatalities occurring between
Tuberculosis Risk Assessment Tool (TReAT)
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2007 and 2014 were defined as time-matched controls (survivors). No particular pairing was
performed as the order of the individuals in the dataset was arbitrary.
The reporting of this study conforms to the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement [17] and to the CHecklist for critical Appraisal
and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) [18].
Data collection
For the derivation set, data was collected from both the HSJ clinical files and the Portuguese
regional surveillance system (SVIG-TB) database. Specifically, information was collected for:
age, gender and lifestyle factors (smoking status and alcohol intake); HIV infection status;
pharmacological immunosuppression; active cancer; diabetes mellitus; liver failure or cirrhosis;
stages 4 and 5 chronic kidney failure; congestive heart failure (CHF); and chronic respiratory
disease (CRD). The definition of the coexistent illnesses is detailed in the footnotes for Table 1.
Baseline clinical features available at time of diagnosis (before patients started treatment) were
collected. These included: time of symptoms onset; the presence of three respiratory (cough,
hemoptysis, dyspnea) and three constitutional symptoms (fever, night sweats, weight loss);
hemoglobin and C-reactive protein (CRP) values; acute hypoxemic respiratory failure (defined
as newly onset partial pressure of oxygen decrease to<60 mmHg, or arterial oxygen saturation
<90%); and digital images of plain chest radiographs. Baseline chest radiographs were blindly
analysed by two independent physicians according to the lesions extent, the presence of lung
cavitation and pleural effusion. Disagreement between readers was resolved through a consen-
sus read by a third physician. Most cases had microscopic examination of auramine-stained
sputum slides, ranking acid-fast bacilli load as negative, 1+, 2+, or 3+ [19] and a drug suscepti-
bility profile was also available. Deaths that occurred during the first 6 months after diagnosis
were classified as TB death [16]. The survival time was calculated between dates of the first
microbiological sampling (which allowed for the provisional diagnosis before culture positivity
could be ascertained) and death. Patients were censored at the date of the last visit if they were
lost to follow-up or at the end of TB treatment. Data were recorded as missing if information
could not be ascertained by review of paper and electronic charts. Missing values within the
derivation set are detailed on Table 1. For the validation set, only cases with complete data for
the predictors included in the clinical score were considered.
Statistical analysis
Univariate analyses were conducted for all variables comparing survivors and fatalities in the
derivation cohort. Continuous variables were recategorized into binary factors. In the absence
of previously described thresholds in the literature, we used the Youden index criterion to esti-
mate the optimal cut-point when giving equal weight to sensitivity and specificity [20]. For cat-
egorical variables, comparisons were made using a Chi-square test or Fisher exact test as
appropriate. For continuous variables, comparisons were made using an independent group t-
test, or a Mann-Whitney U-test for non-normally distributed variables.
Models to predict death in PTB patients were derived using stepwise logistic regression with
6-month mortality as the outcome measure. Eight clinically plausible interactions were tested
(listed in S1 Table). The results of significant predictors were reported as odds ratios (ORs) and
95% confidence intervals (CI). Models were assessed for goodness-of-fit using receiving opera-
tor characteristic (ROC) curves and the Hosmer-Lemeshow test. Then, using the Heckman's
selection model, values of significant variables with missing data were modeled and incorpo-
rated into the initial model to assess and correct for potential bias. This method attempts to
Tuberculosis Risk Assessment Tool (TReAT)
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Table 1. Study population characteristics and comparison between survivor and fatality groups. Continuous variables are presented as mean±SD or
median (25th–75th percentile). The proportions in this table reflect the number of patients with each finding divided by the total number of patients for whom
data were available.
Clinical feature All (n = 681) Survivors (n = 560) Fatalities (n = 121) P value
Age years, median (IQR) 47 (35–64.5) 45 (33–59) 63 (46.5–76.5) <0.001a
Male gender, n (%) 501/681 (73.6) 405/560 (72.3) 96/121 (79.3) 0.112
Former or current smoker, n (%) 341/555 (61.4) 274/470 (58.3) 67/85 (78.8) <0.001a
Comorbiditiesb, n (%) Alcohol abuse 157/602 (26.1) 123/512 (24) 34/90 (37.8) 0.006a
HIV positive 117/615 (19) 91/517 (17.6) 26/98 (26.5) 0.039a
Immunosuppression 42/673 (6.2) 34/553 (6.1) 8/120 (6.7) 0.831
Malignancy 43/672 (6.4) 14/553 (2.5) 29/119 (24.4) <0.001a
Diabetes mellitus 84/677 (12.4) 59/557 (10.6) 25/120 (20.8) 0.002a
Liver failure or cirrhosis 91/669 (13.6) 67/549 (12.2) 24/120 (20) 0.024a
Chronic kidney diseasec 35/676 (5.2) 25/557 (4.5) 10/119 (8.4) 0.080
Congestive heart failure 52/666 (7.8) 32/549 (5.8) 20/117 (17.1) <0.001a
Chronic respiratory disease 109/660 (16.5) 74/544 (13.6) 35/116 (30.2) <0.001a
TB site, n (%) Pulmonary 478/681 (70.2) 393/560 (70.2) 85/121 (70.2) 0.939
Pleural ± pulmonary 90/681 (13.2) 75/560 (13.4) 15/121 (12.4)
Pulmonary + extrathoracic 113/681 (16.6) 92/560 (16.4) 21/121 (17.4)
Time of symptoms (weeks), median (IQR) 7 (4–12) 8 (4–13) 4 (2.8–11) 0.002a
Main symptoms,n(%) Cough 450/577 (78) 374/477 (78.4) 76/100 (76) 0.597
Hemoptysis 99/571 (17.3) 90/475 (18.9) 9/96 (9.4) 0.024a
Dyspnea 240/575 (41.7) 173/472 (36.7) 67/103 (65) <0.001a
Fever 345/578 (59.7) 284/479 (59.3) 61/99 (61.6) 0.668
Night sweats 225/490 (45.9) 195/415 (47) 30/75 (40) 0.264
Weight loss 335/539 (62.2) 271/448 (60.5) 64/91 (70.3) 0.078
Bacillary loadd, n (%) 0 138/477 (28.9) 114/384 (29.7) 24/93 (25.8) 0.823
1+ 64/477 (13.4) 52/384 (13.5) 12/93 (12.9)
2+ 99/477 (20.8) 80/384 (20.8) 19/93 (20.4)
3+ 176/477 (36.9) 138/384 (35.9) 38/93 (40.9)
Drug resistance,n(%) Isoniazidee 30/655 (4.6) 23/545 (4.2) 7/110 (6.4) 0.327
Riphampicin 6/655 (0.9) 5/545 (0.9) 1/110 (0.9) 0.993
Pyrazinamidef 6/294 (2) 5/248 (2) 1/46 (2.2) 0.945
Ethambutol 7/655 (1.1) 5/545 (0.9) 2/110 (1.8) 0.402
Hypoxemic respiratory failure, n (%) 115/595 (19.3) 64/491 (13) 51/104 (49) <0.001a
Hemoglobin g/dL, mean ±SD 12.0 ± 2.2 12.2 ± 2.1 11.0 ± 2.2 <0.001a
CRP mg/L, median (IQR) 79.4 (32.3–126.9) 74.9 (29.2–125.4) 90.5 (42.5–144) 0.011a
Cavitation, n (%) 265/613 (43.4) 219/494 (44.3) 47/119 (39.5) 0.339
Bilateral lung involvement, n (%) 336/598 (56.2) 248/484 (51.2) 88/114 (77.2) <0.001a
Pleural effusion, n (%) 148/605 (24.5) 110/489 (22.5) 38/116 (32.8) 0.021a
aStatistically signiﬁcant results.
bHIV infection = positive titer of antibodies to HIV; Immunosuppression = organ transplant and patients receiving the equivalent of15 mg/day of
prednisolone for1 month, other immunosuppressive drugs, or TNF-α antagonists; Active cancer = any cancer except basal- or squamous cell cancer of the
skin, that was active at the time of presentation; Diabetes mellitus = history of diabetes or fasting blood glucose concentration126 mg/dL at 2 different time
points; Liver failure/cirrhosis = chronic liver disease with coagulopathy and hypoalbuminaemia or a clinical or histologic diagnosis of cirrhosis; Chronic
Kidney Disease = history of chronic renal disease or abnormal blood urea nitrogen and creatinine concentrations documented in the medical record;
Congestive heart failure = systolic or diastolic ventricular dysfunction documented by history, physical examination, chest radiograph and/or
echocardiogram; Chronic respiratory disease = COPD and structural lung disease.
cCKD stages 4 or 5.
dOnly cases of culture conﬁrmation on sputum (the remaining subjects were diagnosed through gastric aspirate, bronchial wash, bronchoalveolar lavage,
pleural ﬂuid or biopsy cultures).
eMissingness of 3.8% due to contaminated culture or non-representative sampling.
fPyrazinamide resistance was not routinely assessed until May 2011.
CRP—C-reactive protein; IQR—interquartile range; HIV—human immunodeﬁciency virus; SD—standard deviation; TB—tuberculosis
doi:10.1371/journal.pone.0162797.t001
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control for the effect of nonrandom selection by incorporating both the observed and unob-
served factors that affect nonresponse [21].
To derive a simple-to-compute risk score, the regression coefficients of the predictors were
divided by the smallest coefficient and then rounded to the nearest integer [22]. For each
patient, a total risk score was obtained by calculating the sum of individual points attributed to
each of the variable.
Three methods were used to validate the CPR. Pearson's Chi-square tests for independence
were performed to test the association between risk score groups and observed deaths on deri-
vation and validation cohorts and for total sample. Association between categories was evalu-
ated based on the adjusted residual scores, where absolute values>1.96 represent significant
differences for 95% confidence level (P<0.05). Significant positive scores reveal a tendency to
observe death in the considered group. To describe the accuracy of the model for predicting
mortality, we reported the sensitivity, specificity and test predictive values. The area under the
ROC curve (AUC) and its 95% confidence interval (CI) were determined and compared in the
derivation and validation cohorts. All the statistical analyses were performed using the SPSS
software program, version 22 (IBM1 SPSS1, Inc.) and STATA, version 14 (STATA Corp) for
Heckman modeling.
Ethics
The study protocol was approved by the Health Ethics Committees of the HSJ (approval num-
ber 109–11), the North Health Region Administration (approval number 71–2014) and the
Portuguese Data Protection Authority (approval number 12174–2011). The requirement to
obtain informed written consent from each individual was waived, as the study was limited to
the review of existing medical records. To ensure confidentiality, each case was anonymized by
the assignment of a random identification number.
Results
Study design
Between 2007 and 2013, 813 culture-confirmed new TB cases were diagnosed at the HSJ (both
inpatient and outpatient), of which 142 (17.5%) were reported to have died within 6 months of
diagnosis. Patients with overall lack of information (n = 40), with exclusively extrathoracic TB
(n = 83) or<18 years (n = 9) were excluded from the study (Fig 1). A total of 681 patients were
included for univariate analysis, including 121 (17.8%) fatalities within 6 months (183 days) of
diagnosis, with median survival time of 33 days (range 1 to 182). Of the 560 not known to have
died, 60 were lost to follow-up after a median of 138.5 days (range 6 to 182) and the remaining
500 were censored at the end of follow-up period. The vast majority of cases included in the
study were Portuguese-born caucasians (96.5%) and only 0.4% of cases harboured multidrug-
resistant strains.
The validation cohort was from an ambulatory referral centre (CDC), which followed 769
patients between 2007 and 2014 and registered a mortality rate of 5.7%. Of the 44 CDC regis-
tered deaths, only 24 patients had complete data. Seventy-nine survivors were included to
match these fatalities, leading to a validation cohort of 103 patients (Fig 1), in a 3:1 ratio (except
for 7 fatal cases, which had 4 matching controls).
Development of a practical CPR to assess risk of death
The general characteristics of the study cohort and specific associations with death are pre-
sented in Table 1. The significant variables were then tested in multivariate logistic regression
Tuberculosis Risk Assessment Tool (TReAT)
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model with 6-month mortality as the dependent variable. Participants were categorized by age
groups, according to a threshold based on Youden index criterion, which defined an optimal
cut-point of 53.5 years (50 years, if rounded to nearest multiple of 10). Hemoglobin<12 g/dL
defined anemia in both genders. Self-reporting variables with more than 20% of missing values
were excluded, as the validity of these data is doubtful. This was the case for smoking, alcohol
habits and time of symptoms. CRD and liver failure/cirrhosis were collinear with smoking and
alcohol abuse, respectively, and worked as surrogates for those exposures. Based on clinical rea-
soning, malignancy was also excluded, as it related to patients with incurable active cancer and
it was strongly associated with mortality itself. Six interactions between variables were identi-
fied, but the resulting ORs were always similar or even lower than with significant variables
alone (S1 Table). In addition to increased complexity, there was no benefit in terms of model
performance to predict risk when these interactions were included. Hence, they were omitted
from the model. Using backward selection [23], a final parsimonious model with 5 predictors
(Table 2, S1 Fig) was generated.
The equation of the prediction model and Heckman’s selection equation were not indepen-
dent (χ2(1) = 5.12, P = 0.023), an argument that justifies the need to apply this procedure. The
marginal effects for each of the predicting variables were compared between both models (S2
Table). The maximum absolute difference found between the two models was 5% (e.g. for
Fig 1. Flow chart for the selection of the participating patients, according to the STROBE guidelines. HSJ—Hospital São
João, Porto, Portugal; CDC—Chest Disease Centre (ambulatory care), Vila Nova de Gaia, Portugal.
doi:10.1371/journal.pone.0162797.g001
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patients with age50 years the probability of death within 6 months of diagnosis was 24%
with CPR model and 29% with Heckman’s model). However, the CPR model correctly identi-
fied the marginal effect associated to each predictor (e. g. when binary variable hypoxemic
respiratory failure changes from 0 to 1, the death probability changes 0.23 for CPR and 0.22
with Heckman’s model). Thus, the use of this model showed that missing information in the
univariate significant variables had little or no effect on mortality risk assessment.
A weight for risk score was calculated for each variable, as describe above (Table 2). The
strongest predictors (major criteria) of mortality were hypoxemic respiratory failure, followed
by age50 years. Minor criteria were bilateral lung involvement, the presence of at least one of
the significant comorbidities (HIV infection, diabetes, liver failure/cirrhosis, CHF, or CRD)
and hemoglobin level<12 g/dL. The accuracy of the model was then tested. A ROC curve was
generated (Fig 2A), showing that the overall sensitivity and specificity of the clinical scoring
system is similar to the logistic regression model.
Development of TReAT: a scoring system to stratify the risk of death in
TB patients
Based on the aforementioned clinical features and using the weights given in Table 2, a scoring
system was constructed to stratify the risk of death among PTB patients using the 2 major risk
factors and the 3 minor ones, and assigning a score from 0 to +8 to each patient (Fig 2B and
2C). The sensitivities, specificities and predictive values of different score values are given in
Table 3. The high sensitivity and negative predictive value obtained for a score below 3 points,
proved that the test performed well to identify cases of reduced death probability when scoring
0 to 2. These cases were included in the low-risk group and only a few died during follow-up
(Fig 2B). The most heterogeneous group was the moderate-risk one, with a gradual decline of
survival during the assessed 6 months. For a cut-off score of6, the specificity and positive
predictive value increased significantly. Thus, most deaths were observed in the high-risk
patients scoring 6 to 8.
Validation of TReAT
TReAT was validated in an independent cohort (Fig 1). By performing the validation in a non-
hospital centre, a more general applicability of the CPR was tested. Importantly, a significant
association was found between group scores (low-, moderate- and high-risk) and real deaths in
the validation cohort and with similar magnitude (P<0.001) to what was observed for the deri-
vation set (Table 4). Furthermore, all comparisons between sets regarding mortality within
each risk group were non-significant. Association between categories was also reinforced based
on the adjusted residual scores, where absolute values>1.96 indicate that the number of cases
Table 2. Multivariable logistic regression analysis for deriving tuberculosis risk score for death.
Predictor Crude OR (95% CI) Regression coefﬁcient Multivariable OR (95% CI) Weight for risk score
Hypoxemic respiratory failure 6.7 (4.2–10.9) 1.543 4.7 (2.8–7.9) 3
Age50 years old 4.2 (2.6–6.8) 1.050 2.9 (1.7–4.8) 2
Bilateral lung involvement 3.4 (2.0–5.8) 0.899 2.5 (1.4–4.4) 1
At least 1 signiﬁcant comorbiditya 3.4 (2.1–5.4) 0.813 2.3 (1.3–3.8) 1
Hemoglobin <12 g/dL 2.5 (1.6–4.0) 0.600 1.8 (1.1–3.1) 1
a At least one of these comorbidities: HIV infection, diabetes mellitus, liver failure or cirrhosis, congestive heart failure and chronic respiratory disease.
CI—conﬁdence interval; OR—odds ratio
doi:10.1371/journal.pone.0162797.t002
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in those cells are significantly larger in moderate and high-risk groups (positive relation), or
smaller in the low-risk group (negative relation), than would be expected if the null hypothesis
were true, with a significance level of 0.05. In support of the generated assessment tool
(TReAT), there was no significant difference in the AUCs between the derivation (0.82, 95% CI
0.78–0.87) and the validation cohorts (0.84, 95% CI 0.76–0.93; P = 0.72).
Discussion
This study offers, to the best of our knowledge, the first CPR for TB death prognosis in a high-
income region of low to intermediate TB incidence, without expressive multi-drug resistance,
comprising both hospital and ambulatory settings. The aim of this CPR is to signal confirmed
Fig 2. A—ROC curve for the logistic regression model (clinical prediction rule equation, S1 Fig) and clinical scoring system (0 to 8
points) | B—Kaplan-Meier estimates of survival in low-risk (clinical score 0–2), moderate-risk (clinical score 3–5) and high-risk (clinical
score 6–8) tuberculosis patients. The mortality in each group at different time-points is shown below | C—TB risk assessment tool
(TReAT), using baseline clinical features for stratifying patients with pulmonary tuberculosis into severity groups according to the
probability of death at 6 months.
doi:10.1371/journal.pone.0162797.g002
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cases of TB who are at higher risk of death and thus need a stricter medical supervision. Other
TB scoring systems have been previously developed, but a few limitations likely hinder their
use in this specific context. To the best of our knowledge, only three prognostic rules have been
developed for TB. Wejse et al. proposed the first prediction rule (the Bandim TBscore) in a
low-resource country (Guinea-Bissau), based on five symptoms and six clinical signs [14].
There are a few reasons why this score may not be applicable to our setting: i) it was never vali-
dated in a high-income region, which has very different epidemiological features and better
healthcare access; ii) a large proportion of the patients included in the Bandim TBscore study
were HIV-infected and had no antiretroviral treatment available, which could independently
affect mortality; and iii) in the same study more than half of the cases were smear negative and
had no culture confirmation of TB diagnosis. In our cohort, smear negative cases comprised
only one third of the subjects, mostly old and HIV-infected patients, but all had culture-proven
TB. Another prognostic score was developed by Horita et al. to predict in-hospital death in a
context similar to ours [6]. However, the analysis was biased by excluding multidrug resistant-
TB and HIV-infected subjects, which are known to increase mortality [3, 4, 24, 25]. Also, other
comorbidities were not included in their score and diabetes was not significantly associated to
death (possibly due to the small sample size), contrarily to the majority of other studies [26–
28], including the present one. By including coexistent conditions in TReAT, the weight given
to age was attenuated, as young patients with diseases, like HIV/AIDS and liver failure/cirrho-
sis, were also considered at risk. Moreover, all patients included in the Horita et al. study
were admitted to the ward, which is hardly representative for the overall population of
Table 3. Test characteristics with different prediction scores for mortality in the derivation cohort of patients with pulmonary tuberculosis.
Score n (%) Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
0 539 (100) 100 0 17.8 NA
1 466 (86.5) 98 16.1 20.6 97.3
2 380 (70.5) 96.9 35.4 25 98.1
3 294 (54.5) 92.9 54 31.0 97.1
4 203 (37.7) 79.6 71.7 38.4 94
5 133 (24.7) 62.2 83.7 45.9 90.9
6 76 (14.1) 41.8 92.1 53.9 87.7
7 49 (9.1) 27.6 95 55.1 85.5
8 23 (4.3) 12.2 97.5 52.2 83.3
NA—not applicable; NPV—negative predictive value; PPV—positive predictive value
doi:10.1371/journal.pone.0162797.t003
Table 4. Comparison of risk groupsmortality in the derivation and validation cohortsa.
Derivation cohort Validation cohort Total sample
Deaths (n,%) arb Deaths (n,%) ar Deaths (n,%) ar
Low risk (score 0–2) 7/245 (2.9) -8.4 2/54 (3.7) -4.9 9/299 (3) -9.6
Moderate risk (score 3–5) 50/218 (22.9) 2.4 13/38 (34.2) 2.0 63/256 (24.6) 2.9
High risk (score 6–8) 41/76 (53.9) 8.7 9/11 (81.8) 4.9 50/87 (57.5) 9.8
Total 98/539 (18.2) 24/103 (23.3) 122/642 (19)
aAssociation between risk groups and real deaths for derivation cohort (χ2 = 107.3, P<0.001) and for validation cohort (χ2 = 35.2, P<0.001) were signiﬁcant.
The P values for the comparisons of real mortality between sets for each risk groups are as follows: low-, P = 0.67; moderate-, P = 0.15; high-, P = 0.11.
bAbsolute values >1.96 represent signiﬁcant differences for 95% conﬁdence level (P<0.05). ar—Adjusted Residual scores
doi:10.1371/journal.pone.0162797.t004
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culture-positive TB patients, since in many European countries, including Portugal, TB treat-
ment is done largely outside the hospital setting. Finally, Valade et al. [15] assessed only 53
cases to propose a prognostic scoring system for TB patients admitted to the intensive care
unit. It will be interesting, in future, to compare TReAT with each of these scores and analyse
their relative performance and applicability to different settings.
In the present work, the fatal outcome was determined until 6 months after diagnosis,
which is supported by several studies, including clinical trials [29–31], and contemplates the
minimum duration of the standard multidrug treatment. Late mortality related to TB was pre-
viously described to stabilize after 6-months of treatment [30]. Nevertheless, patients died
more frequently during the first 30 days after diagnosis, which did not appear to be related
with diagnostic delay, since fatal cases usually had shorter time of symptoms compared to sur-
vivors (Table 1). Our results thus suggest that high-risk subjects are usually severely ill from
the beginning and should, therefore, be strictly followed and start anti-TB drugs under close
monitoring. Initial care in an intensive care or high dependency unit may be appropriate for
some cases, particularly because they may have a slow response to standard treatment regi-
mens. The mortality in the derivation cohort (17.5%) was higher than the national estimate
(6.4%) [1] and that of the validation cohort (5.7%). This is in line with the described worse TB
outcome in hospitalized patients [32, 33]. However, in-hospital mortality due to PTB seems
underestimated, when those who require advanced respiratory support face a much higher
death rate (up to 70%) than subjects with respiratory failure due to other causes [34].
One of the strengths of this study was the clear definition of our predictor variables, which
are not dependent on patient’s recall or susceptible to clinicians’ subjective judgement. The
proposed prediction model is based on intrinsic patients’ characteristics (age and comorbidi-
ties), disease extent (respiratory failure and one radiographic feature) and a measure of con-
sumption and overall nutritional status (hemoglobin level). The relevance of these variables to
the outcome of TB is in line with previous studies [3–7, 14, 31, 34–36].
Limitations of the current study include its retrospective nature and the fact that the valida-
tion set is relatively small. Owing to the retrospective design of the study, a significant number
of missing values were found in certain variables. The causes of non-random missing informa-
tion are very heterogeneous, mainly dependent on the patient status, or on the clinicians, who
were of different medical specialties, acting in different settings (emergency room, ward, ICU,
outpatient clinic), and may have neglected differential data. For instance, there was a 12.6% of
missingness in the “hypoxemic respiratory failure” variable. It is possible that less severe
patients without any signs of respiratory distress were not assessed for hypoxemia. On the
other hand, patients who were admitted at the busy emergency room and who died during the
first 24-48h after admission may have had a short description of his/her clinical condition or
past history. Also, 66 patients (9%) of the derivation cohort were not tested for HIV. In a recent
work [37] with 7683 TB cases notified in Northern Portugal between 2006 and 2012, 879
(11%) had also unknown HIV status (usually older patients or without history of addiction).
We addressed the missingness issue by applying the Heckman method and showed the little
impact on the validity of the prediction model. Moreover, sample collection was based in two
centres with geographical proximity. It is however important to note that these centres had
very different characteristics (hospital versus ambulatory) and yet the accuracy of TReAT was
similar. Considering the small validation set, it will undoubtedly be of interest to test this CPR
prospectively to other surroundings, in whole cohorts or in multicentric studies that would
allow larger sample sizes.
The WHO has recently launched the End TB Strategy, which defined the lines towards TB
elimination [38]. Among the discussed requirements was the importance of monitoring treat-
ment outcomes. As TB incidence rates decrease with a combination of near-universal access to
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high-quality diagnosis and treatment and general socioeconomic development, it is expected
that the TB death rate will become one of the core indicators for disease control [11]. Imple-
mentation of a CPR to identify patients who are more likely to die may prompt screening ini-
tiatives in particular risk groups and point directions for further programmatic interventions.
On the other hand, the great variability of reported rates of hospital admission and lengths of
stay for TB [39, 40] may reflect the uncertainty among clinicians regarding the definition of
severity of illness. We expect that the proposed TReAT helps to bridge these gaps, providing
more cost-effectiveness use of medical resources by selecting more appropriately patients that
will need closer clinical surveillance.
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